Form 4: AIM ImmunoTech CEO Increases Stake Through Open Market Purchase
Insider Transaction Report
AIM ImmunoTech Inc.'s CEO and President, Thomas K. Equels, acquired 107 shares of common stock at $7.697 per share, increasing his direct beneficial ownership to 38,885 shares.
Summary
- Thomas K. Equels, who serves as CEO & President and Director of AIM ImmunoTech Inc. (AIM), reported a transaction.
- On June 13, 2025, Mr. Equels acquired 107 shares of AIM ImmunoTech Inc. common stock.
- The shares were purchased at a price of $7.697 per share.
- Following this transaction, Mr. Equels directly beneficially owns a total of 38,885 shares of common stock.
- The transaction was conducted pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
Sentiment
Score: 7
Explanation: The CEO's purchase of company stock, even a small amount, generally signals confidence in the company's valuation and future prospects, contributing to a moderately positive sentiment.
Positives
- The CEO's purchase of company stock, even a modest amount, generally signals confidence in the company's current valuation and future prospects.
- The transaction was executed under a Rule 10b5-1(c) plan, which suggests a pre-planned investment strategy and adherence to insider trading compliance protocols.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Utilization | The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy designed to comply with insider trading laws and provide an affirmative defense against insider trading allegations. | NA | Enhances transparency and reduces the perception of opportunistic insider trading by demonstrating a structured approach to insider stock transactions. |
Related Party Transactions
- Thomas K. Equels, CEO & President and Director of AIM ImmunoTech Inc., purchased 107 shares of the company's common stock from the open market.
Stakeholder Impact
- Shareholders may interpret the CEO's stock purchase as a positive signal of management's belief in the company's intrinsic value and future performance.
Key Dates
| Date | Description |
|---|---|
| 06/13/2025 | Date of common stock acquisition by Thomas K. Equels. |
| 06/16/2025 | Date the Form 4 was signed and filed with the SEC. |
Keywords
AIM ImmunoTech, AIM, Thomas K Equels, insider trading, Form 4, stock purchase, CEO, beneficial ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.